


著効率

BMS-790052 NS5A inhibitor 60mg QD

BMS-650032 Protease-inhibitor 600mg BID

Null-responder genotype 1 patients (n=21)



Viral breakthrough in 6 pts in Gr.A between wks 2 and 12 (NS3+NS5B variants in all patients detected)


Viral relapse occurred in 1 patient from DUAL at post-treatment week 4

QUAD: 1 patient had HCV-RNA < LLOQ at FU24 but neg. 35 day later

Lok et al, EASL 2011, oral

Genotype 2/3症例におけるPSI-7977+PEG/Rの治療効果

- Treatment naïve HCV genotype 2/3 infected patients (n=25)[1 patient lost to follow-up after first dose]
- PSI-7977 400mg QD plus PEG/R for 12weeks



No viral breakthrough
No AE leading to discontinuation

Lalezari et al., EASL2011